25 C
Vientiane
Saturday, May 24, 2025
spot_img
Home Blog Page 287

ADQ, IHC and Modon form new infrastructure platform ‘Gridora’ to accelerate the development of strategic projects

  • The new entity, ‘Gridora’, will be a joint venture operating under Modon Holding
  • Gridora will collaborate with specialist partners and capital providers to advance the delivery of strategic infrastructure projects nationally, regionally and internationally
  • The platform is strategically positioned to enhance and foster long-term collaboration between the public and private sectors

ABU DHABI, UAE, April 17, 2025 /PRNewswire/ — Leading Abu Dhabi-based global entities ADQ, IHC and Modon Holding have entered into a joint venture to form a dedicated infrastructure platform that will actively drive infrastructure development for private and public-private partnerships. Operating under Modon Holding, Gridora will serve as a strategic platform for collaboration with specialist partners and capital providers, enabling the delivery of large-scale, high-impact infrastructure projects.

Bridge to Hudayriyat Island
Bridge to Hudayriyat Island

Leveraging Modon Holding’s national, regional and international infrastructure and real estate development expertise, the new entity will accelerate the delivery of major projects across the UAE and globally. It will enhance capacity for deployment, streamlining the procurement and implementation of key infrastructure contracts.

Gridora will be structured around two complementary business lines, Infrastructure Projects and Infrastructure Investments, which reflect the project origination and asset management capabilities of its founding partners. This dual-focus model is designed to generate returns, while addressing the transformative shift required to scale infrastructure implementation nationally, regionally and internationally.

By assuming a leadership role in critical delivery processes, Gridora will create value throughout the infrastructure lifecycle – from early-stage planning through to operations – unlocking new opportunities for both fee-based revenues and long-term investment yields. With the combined strength of its three founding partners, Gridora is strategically positioned to foster long-term collaboration between the public and private sectors.

Commenting on the partnership, His Excellency Jassem Mohamed Bu Ataba Al Zaabi, Chairman of Modon Holding, said: “Abu Dhabi’s thriving economy and growing population demand world-class infrastructure. By leveraging the collective expertise and resources of ADQ, IHC and Modon Holding, Gridora will become a local, regional, and international champion for infrastructure development and drive a step change in delivering strategic projects.” 

His Excellency Mohamed Hassan Alsuwaidi, Managing Director and Group Chief Executive Officer of ADQ, said: As a long-term investor with deep exposure across infrastructure investments, the establishment of Gridora exemplifies our commitment to design and enable transformative development for projects of strategic importance. Our partnership with world class institutions, such as Modon and IHC, aims to unlock further value through this platform, and it is a reflection of our growing confidence to drive innovation and efficiency built for long term impact for the emirate and beyond.”

Syed Basar Shueb, Chief Executive Officer of IHC, added: “Gridora reflects IHC’s continued focus on building future-ready platforms that combine innovation, scale, and strategic collaboration. As a long-term investor, we see strong potential in harnessing infrastructure investments to unlock new economic value, deepen private sector participation, and drive infrastructure-led growth across markets. With Modon as part of the IHC Group, this joint venture reinforces our strategy of empowering our dynamic value networks to lead in sectors that are vital to national and regional development.”

Bill O’Regan, Group Chief Executive Officer of Modon Holding, said: “The joint venture reinforces Modon’s mission to create smart cities defined by intelligent and connected living. It provides a targeted solution to meet infrastructure requirements, significantly accelerating the delivery of critical projects while broadening the field of specialist private sector delivery partners. Gridora will harness Modon Holding’s pioneering capabilities to channel expertise and capital into key projects and builds on Abu Dhabi’s proven framework for development of transformative infrastructure. Alongside expediting the delivery of state-of-the-art infrastructure, it will also open new revenue streams and attractive long-term opportunities for Modon Holding and our partners.”.

About ADQ:

Established in 2018, ADQ is an active sovereign investor with a focus on critical infrastructure and global supply chains. As a strategic partner to the Government of Abu Dhabi, ADQ invests in the growth of business platforms anchored in the Emirate that deliver value to local communities and long-term financial returns to its shareholder. ADQ’s total assets amounted to USD 225 billion as of 30 June 2024. Its rapidly expanding portfolio encompasses companies across numerous core sectors of the economy, including energy and utilities, transport and logistics, food and agriculture, and healthcare and life sciences.

For more information, visit adq.ae or write to media@adq.ae.

You can also follow ADQ on Instagram, LinkedIn and X

About IHC:

Established in 1999, IHC has become the most valuable holding company in the Middle East and one of world’s largest investment firms, with a market capitalization of AED 876.5 billion (USD 238.5 billion). Since then, it has transformed to represent a new generation of investors. IHC’s commitment to sustainability, innovation, and economic diversification spans over 1,200 subsidiaries, driving growth across industries like Asset Management, Healthcare, Real Estate, Financial Services, IT, and more.

IHC continually looks beyond the stand-alone value of its assets for opportunities, stepping outside of traditional approaches and artificial barriers to unlock opportunities across its portfolio, enabling sector-agnostic Dynamic Value Networks and creating results that are often much greater than the sum of their parts.

At IHC, we take our responsibility to shareholders, customers, and employees seriously. Our commitment to responsible investment ensures that we create sustainable value by staying connected to the communities we serve, making a positive difference with every investment.

www.ihcuae.com

About Modon:

Modon is an international holding company, headquartered in Abu Dhabi, United Arab Emirates, and listed on the Abu Dhabi Securities Exchange (ADX). We are at the forefront of urban innovation, creating iconic designs and experiences that continually surpass expectations. Our primary business sectors include real estate, hospitality, asset management, investments, events, and tourism. Our goal is to deliver long-term, sustainable value, laying the foundations for intelligent, connected living.

For further information, please contact:
press@modon.com
ir@modon.com
www.modon.com 

 

 

 

 

Terumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US

 – Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort –

SOMERSET, N.J., April 17, 2025 /PRNewswire/ — Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced that Medis QFR 3.0, an FDA-cleared software solution for coronary physiology assessment, is now available in the United States through its collaboration with Medis Medical Imaging. This milestone builds on the companies’ December 2023 partnership announcement.

“Helping hospitals access proven, innovative tools like QFR 3.0 is an important part of our mission,” said Ryan Graver, Senior Divisional Vice President, THO. “This latest advancement from Medis aligns with the goals of many hospitals to enhance cath lab efficiency and support high-quality, patient-centered care. We are proud to be able to offer this cardiology diagnostic software solution to our customers.”

THO and Medis will showcase QFR 3.0 during the upcoming SCAI 2025 Scientific Sessions, offering clinicians the opportunity to learn more about the technology and its role in supporting efficient, physiology-guided care in the cath lab.

Medis QFR has been validated through extensive clinical research, including over 200 peer-reviewed publications and data from more than 17,000 patients and 20,000 lesions. In 2024, QFR was recommended by the European Society of Cardiology in their ESC Guidelines, reinforcing its clinical relevance and utility.

“We’re excited that U.S. hospitals will now have access to QFR 3.0,” said Dr. Maya Barley, CEO of Medis Medical Imaging. “Our continued collaboration with Terumo Health Outcomes supports our goal of delivering solutions that simplify workflow while maintaining a strong foundation of clinical accuracy.”

“This partnership reflects our shared commitment to expand hospital access to innovative cardiovascular technologies,” said Ghada Farah, President of Terumo Interventional Systems.

THO is a division of TIS, which offers a portfolio of high-quality interventional devices that complement the predictive insights offered by THO’s ePRISM platform. While ePRISM assists clinicians in identifying patient risk and optimizing treatment strategies, the advanced tools from TIS support procedural efficiency, contributing to improved patient outcomes. This combination assists clinicians to make more informed decisions, facilitating smoother procedures and potentially reducing hospital costs and recovery times.

About Terumo Health Outcomes
Terumo Health Outcomes (THO) delivers advanced digital health solutions that empower clinicians with predictive insights to optimize patient care and hospital efficiency. The ePRISM platform helps provides personalized patient care, which is provided to the clinician on a screen in real-time as a decision support tool, enabling hospitals to implement data-driven care strategies that enhance patient outcomes and streamline operational performance. Learn more at www.terumohealthoutcomes.com.

About Terumo
Terumo (TSE:4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for over 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large. More information can be found at www.terumo.com.

About Medis Medical Imaging
For over 35 years, Medis has been providing innovative, robust, and extensively validated tools to the medical community worldwide. The heritage and core values are based on this strong purpose of contributing to a healthier society by providing the right tools to cardiologists, radiologists, researchers, and industry partners. Medis’ software is internationally appreciated due to its ease of use and its clinical outcome for the patients. At Medis, quality is key. All products are developed and validated extensively to guarantee the highest quality, without compromise. They continuously focus on the creation of clinically relevant innovative software solutions in the cardiovascular imaging domain.

 

 

BLUETTI Apex 300 Pre-Launch: Next-Gen Versatile Energy with Exclusive Access Open Now

The Apex 300 is built for a simple start—and ready to scale into a smarter energy ecosystem.

LAS VEGAS, April 17, 2025 /PRNewswire/ — BLUETTI, a leader in portable power and energy storage, today announced the pre-launch of its versatile Apex 300 Energy Storage System(ESS). Designed for robust standalone use with a simple plug-and-play setup and low initial investment, the Apex 300 unlocks its full potential through an expandable ecosystem that scales for emergency backup, whole-home backup, and off-grid living.


The Apex 300 is built for tough, standalone performance with a simple plug-and-play setup and low initial cost. Its real strength lies in its expandable ecosystem, allowing it to easily scale to handle emergency backup, whole-home power, and even off-grid living.

From now through May 7th, early adopters can unlock exclusive perks through BLUETTI’s pre-launch program—before the official Indiegogo debut at 8:00 AM PDT on May 8th.

Start Simple, Compact, and Powerful

The Apex 300 stores 2,764.8Wh of capacity in a compact package with 40% higher energy density in its class. Despite its compact size, it delivers 3,840W and dual 120V/240V output on a single unit, to power 99% household appliances from fridges to high-power tools, pool pumps, and clothes dryers.

As the world’s first portable power station with 50A/12,000W bypass capability, the Apex 300 alone is fully capable of running an entire house or charging a Tesla EV. The true 0ms Uninterrupted Power Supply (UPS) ensures seamless power for critical systems like lighting, NAS storage and more during blackouts. The ultra-low 20W AC idle drain places it among the most efficient systems in its class—extending refrigerator runtime by up to 24 hours, prolonging AC standby by 2.5 times, and increasing CPAP usage by 2.5 times.

Scale Smart for Diverse Needs

What sets the Apex 300 apart is its smart ecosystem—easily expandable in output, capacity, and versatility through its ecosystem accessories, including:

  • B300, B300S, B300K Expansion Battery – Adds more energy storage.
  • SolarX 4K Charge Controller – 500V/4,000W PV voltage regulator for high-voltage solar arrays.
  • AT1 Smart Distribution Box – Automates energy management for homes.
  • Hub A1 Parallel Box – Expands storage and power output in a parallel system.
  • Hub D1 DC Power Hub – Provides 700W DC output with a 12V/50A Anderson port.
  • S1 Smart Plug – Optimizes energy use for appliances.
  • Car DC to DC Alternator Charger 1– Offers 560W charging power from vehicles’ alternators.

Smart Backup Power for Modern Homes

Whether for emergency backup or whole-home backup, the Apex 300 grows with users’ needs. It scales up to three units and 18 B300K batteries, tripling the power up to 11,520W output and 58,000Wh capacity, enough to keep a home running for an entire week.

The Apex 300 also helps homeowners create a fully automatic whole-home backup system with up to 30,720W solar input, by pairing with BLUETTI’s smart ecosystem—including the AT1 Smart Distribution Box, Hub A1 Parallel Box, and up to three SolarX 4K Charge Controllers.

Seamlessly integrating with existing rooftop solar inverter systems, this home battery backup allows users to manage loads, set power priorities, and activate smart modes like Extreme Weather Alerts via the BLUETTI App. With the AT1 and the S1 smart plugs, homeowners can intelligently manage solar energy, grid electricity, auto-start a gas generator, and appliances through the app.

Reliable Power for RV and Off-Grid Living

The Apex 300 caters to an off-grid lifestyle as well. It has four standard AC outlets to power A/Cs, microwaves, coffee makers, and other outdoor essential appliances. With integrated NEMA TT-30R and NEMA 14-50R ports, it also works as mobile shore power to directly charge all RVs. 

To charge phones, laptops, and other DC devices, RVers can pair it with the 700W Hub D1, a clip-on mountable DC power hub with seven outlets, including two 100W USB-C, two 15W USB-A, two DC5521, and a 12V/50A Anderson port for safer and easy-to-use DIY setup.

Recharging off the grid is just as effortless. Users can refuel it via EV chargers, gas generators, solar panels, or vehicles via the Car DC to DC Alternator Charger 1, which captures unused engine power to provide up to 560W of fast, on-the-go recharging.

Longer Lifespan and Bigger Return

  • Fastest Payback in 2 Years
    Paired with the SolarX 4K—the world’s first 500V/4,000W PV voltage regulator designed for portable power stations—the system pays for itself in just 2 years. This ensures long-term savings for those powering off-grid cabins or integrating solar into their homes.
  • 17 Years of Reliable Use
    Built on the proven success of the Elite 200 V2 Solar Generator, the Apex 300 takes durability and safety to the next level with 2nd-gen automotive-grade LiFePO₄ cells. Engineered to deliver up to 17 years of dependable service, it’s the ideal power solution for homes, RV living, and demanding off-grid environments.
  • Maximum Value, Minimal Footprint
    With hot-swappable batteries and 40% higher energy density, the Apex 300 delivers full power in a compact form, seamlessly switching between scenarios. This allows users a simple unplug-and-go experience for outdoor use, all while maintaining uninterrupted household power.

Be the First to Experience Apex 300

The Apex 300 Pre-Launch exclusive access opens from April 16th to May 7th. Early supporters can secure priority shipping, supplementary gifts, and exclusive benefits with a $10 deposit— recognizing the trust and enthusiasm that help bring new energy solutions to life.

BLUETTI is inviting everyone to join the Apex 300 Global Community and experience the future of portable, scalable energy firsthand. The official Indiegogo launch of the Apex 300 will start at 8:00 AM PDT on May 8th.

About BLUETTI

As a technology pioneer in clean energy, BLUETTI provides affordable clean energy storage solutions for both indoor and outdoor use. Through initiatives like the LAAF (Lighting An African Family) program, BLUETTI aims to power 1 million African families in off-grid areas. Focusing on innovation and customer needs, BLUETTI has become a trusted industry leader in over 110 countries and regions.

Media Contact

Ellen Lee
PR Specialist
ellenlee@bluetti.com

BLUETTI Pre-Launches the Apex 300: A versatile energy storage system for home backup, RVs, off-grid living, and beyond.
BLUETTI Pre-Launches the Apex 300: A versatile energy storage system for home backup, RVs, off-grid living, and beyond.

From Sci-Fi to Daily Life: Service Robots Step into Spotlight at 137th Canton Fair

GUANGZHOU, China, April 17, 2025 /PRNewswire/ — Once confined to the realm of science fiction, robots are now becoming an integral part of a consumer’s everyday routines. At the 137th China Import and Export Fair (Canton Fair), this transformation is more apparent than ever with the debut of its first-ever Service Robots Zone. This dedicated area, spanning 4,200 square meters and featuring 46 companies, showcases how robotics is entering daily life in practical and personal ways, such as brewing morning coffee, trimming lawns, assisting with household chores, and more, bringing the future directly into people’s daily lives.

For coffee lovers needing a caffeine kickstart, they can enjoy a coffee made by the coffee barista robot created by AUBO Robotics. Designed with synchronized robotic limbs and an autonomous learning system, the robot performs the entire coffee-making process, from tamping and extraction to intricate milk frothing. With capacity for 300 cups per day and real-time online upgrades, it’s a barista that never tires. As an expert on collaborative robots, AUBO also presented a massage robot onsite, attracting many buyers.

Dreame Technology’s AI-powered weeding robot makes backyard maintenance a hands-free affair. Equipped with 3D laser radar sensors and forward-facing cameras, this robot maps boundaries and avoids obstacles with high precision. Its floating blade system adapts to grass height and terrain, all while being ready to use right out of the box.

Pool owners also have reason to celebrate. Seauto Robots showcases its SAT 20 series pool cleaning robots, boasting enhanced battery capacity and smart navigation for thorough, corner-to-corner cleaning. With multiple modes and market-leading performance, these robots deliver a sparkling clean with minimal effort.

For restaurant dining, consumers may also have the chance to meet Keenon Robotics’ T10 service robot, designed to deliver meals with grace. Capable of navigating narrow 59cm aisles while carrying up to 40kg, it features a new-generation shock-absorption chassis for smoother deliveries. Customizable with interactive head motions and decorative accessories, it brings both function and personality to the dining experience.

As robotics evolve at breakneck speed, new applications are entering our lives faster than ever. By introducing the Service Robots Zone, the Canton Fair is not only showcasing these innovations but connecting global buyers with the future of smart living. By facilitating meaningful exchanges across the industrial chain, the Fair highlights that the golden age of robotics is here.

 

 

 

SMU Strengthens Career Readiness with Co-Curricular Transcript and Lifelong Career Support

SINGAPORE, April 16, 2025 /PRNewswire/ — At the SMU Co-Curricular Symposium – Nurturing Holistic & Career-Ready Scholars, Singapore Management University (SMU) reaffirmed its commitment to equipping students and alumni with the skills and resilience needed for a dynamic workforce. Education Minister Chan Chun Sing was the Guest-of-Honour at the Symposium and delivered the opening speech.

Singapore Education Minister Chan Chun Sing at the SMU Co-Curricular Symposium 2025
Singapore Education Minister Chan Chun Sing at the SMU Co-Curricular Symposium 2025

As part of its 25th Anniversary celebrations, SMU proudly announced that its graduating class of 2025 will be the first to receive the Co-Curricular Transcript (CCT), a groundbreaking initiative launched in 2023. This milestone reflects SMU’s commitment to nurturing graduates who are not only academically strong but also agile, self-aware, and ready for the demands of the modern workplace. Coupled with access to the newly launched Lifelong Career Support from 1 May 2025, all alumni can confidently navigate career shifts with confidence, at any stage of their professional journey. This is timely, with mid-career job transitions surging in Singapore and the recent instability experienced by the global economy.

Delivering the opening address, Education Minister Chan Chun Sing commended SMU for its leadership in pioneering the CCT, outlining four key qualities that students should cultivate — Curiosity, Connection, Creation, and Contribution — to thrive in today’s rapidly evolving world.

The Co-Curricular Transcript, in its rightful spirit, is for our people to better understand our strengths and weaknesses, and to know how to use those strengths to make a positive contribution to society. It is about finding yourself, understanding yourself, and using what you have to make a meaningful contribution.

Speaking to an audience of over 200 educators, industry partners, and students, Professor Alan Chan, SMU Provost, said that he is proud that the University is setting the industry standard, and emphasised the University’s mission in preparing future-ready graduates.

“At SMU, we believe that learning extends beyond the classroom. As the first university in Singapore to integrate internships, community service, and global exposure as formal graduation requirements, we have always championed a holistic approach to education.

“The Co-Curricular Transcript builds on this strong foundation by further strengthening our students’ real-world competencies through enhanced co-curricular learning and empowering them to articulate their experiences with greater confidence and clarity. This will give our students a much-needed edge in today’s competitive job market,” he said. 

The CCT complements traditional academic transcripts by documenting students’ holistic learning experiences. It categorises students’ participation and growth into three progressive levels — Exposure, Integration, and Transformation — while awarding digital badges for attaining Graduate Learning Outcomes.

As internships, community service and global exposure are formal graduation requirements for SMU students, the information could be effectively captured. This structured record provides employers with deeper insights into graduates’ capabilities beyond academic grades.

SMU’s Integrated Co-Curricular Management System (ICMS) enables the CCT, allowing students to track their learning experiences, submit reflections, and receive educators’ feedback. Early student feedback collected by SMU’s Co-curriculum Development unit from over 200 students in September 2022 found that 81.1% agreed that ICMS features make their co-curricular involvement more purposeful, while 97.5% supported having a formal co-curricular record issued upon graduation.

This initiative is particularly timely as skills-based hiring gains traction globally. According to LinkedIn, 73% of recruiters now prioritise competencies over degrees. In Singapore, 70% of employers place greater value on soft skills like communication and critical thinking than hard credentials. SMU’s CCT bridges this gap by making these essential skills visible to prospective employers.

Today’s hiring landscape is rapidly shifting towards a skills-first approach. Employers are looking beyond traditional credentials to assess a candidate’s adaptability, leadership, and problem-solving abilities. SMU’s Co-Curricular Transcript is highly effective in giving graduates a tangible way to showcase their competencies and stand out in an increasingly competitive job market,” said Elsie Ng, Head of Singapore, LinkedIn.

Since its inception, SMU has consistently pioneered initiatives that equip students with the skills demanded by employers. With 89.8% of SMU graduates securing employment within six months, the CCT further strengthens their competitiveness in a skills-driven economy.

Employers are encouraged to look at the CCT not just as conversation starters, but also use the entries to learn more about the student’s initiative, mindset and values to inform their shortlisting process. Unlike a report card or checklist, students are also guided to be more intentional about their choices of activities, and to more consciously develop a range and mastery of skills for possible alignment towards their professional goals.

SMU Pioneers Lifelong Career Support as Job Market Shifts

With mid-career job transitions surging in Singapore and 64% of alumni expressing interest in career coaching services, SMU is also breaking new ground by becoming the first Singaporean university to institutionalise lifelong career support. Effective 1 May 2025, fittingly, on Labour Day, all SMU[1] degree holders; undergraduate and postgraduate regardless of their graduation year, will have lifetime access to structured career support, a privilege traditionally reserved for recent graduates.

This bold move aligns with national efforts such as SkillsFuture to strengthen career resilience and lifelong learning in an ever-evolving job market, setting a new standard for higher education institutions in preparing graduates for long-term workforce adaptability.

For Richie Sison, an SMU MBA graduate (2021, Philippines), career coaching was pivotal in transitioning from finance to supply chain and operations. “SMU Career Services has been instrumental in helping me pivot from the finance industry to supply chain and operations.  The advice and support from the coach has enabled me to land a role as a Supply Chain Manager at Amazon Singapore, which later opened doors for me to move to Uber Eats in Taiwan as an Operations Manager. The launch of life-long career coaching for alumni will be invaluable as we navigate through new career opportunities throughout our lives.”

“The workforce of tomorrow is being reshaped faster than ever, and universities must take the lead in ensuring graduates are prepared for it,” said Professor Alan Chan, SMU Provost. “SMU is redefining what it means to support graduates, not just at the start of their careers, but for life. We are the first in Singapore to institutionalise and offer lifelong career support, ensuring that no matter how industries shift, our alumni always have a partner to help them adapt, grow, and thrive.” 

The Co-Curricular Symposium has attracted significant attention from institutions across Singapore, including junior colleges, polytechnics and other universities — many of which are exploring similar approaches to documenting co-curricular learning. The foundations of the transcript were also developed in partnership with employers ensuring the relevancy of the learning outcomes.

As a leader in transformative education initiatives, SMU is also the first university in Singapore to make community service a graduation requirement for all students since 2000, and we have collectively devoted more than 4.28 million hours in service towards the community.

For more information on SMU’s transformative educational initiatives, visit SMU’s website.

END

1. [1] Not applicable to exchange students & non-matriculated participants of SMU-A and ExD programmes, and all other Honorary and Associate alumni.

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

SHANGHAI, April 16, 2025 /PRNewswire/ — Henlius (2696.HK) held its 2025 Global R&D Day under the theme of “Collaborate to Create”. Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the industry to engage in in-depth discussions on the latest advances in R&D, future strategic planning, and the deployment of cutting-edge technologies and therapies. The event drew hundreds of guests from academia, industry, and the investment community, making it a grand gathering of shared insight and collaboration.

Jason Zhu, Executive Director and CEO of Henlius, stated: “At Henlius, we remain steadfast in our patient-centric philosophy and continue to strengthen our differentiated competitive edge through innovation-driven R&D. We are advancing the development of several key innovative assets, including HANSIZHUANG (serplulimab, anti-PD-1 mAb), HLX22 (anti-HER2 mAb), and HLX43 (PD-L1 ADC), with the potential to reshape the treatment landscape for lung and gastrointestinal cancers. Beyond that, we are actively exploring frontier technologies such as targeted therapies, immunotherapies, and glyco-editing, as we build a diversified innovation platform. In terms of global expansion, Henlius is strategically focused on major markets such as the U.S., EU, and Japan. Through full value chain integration and deepening international partnerships, we are making a strategic leap from exporting products to building a global value chain. Looking ahead, Henlius will continue to focus on antibody drug innovation, accelerate breakthroughs in targeted and immune therapies, and drive the global advancement of China’s innovative biologics. Our goal is to deliver high-quality, affordable biologics to patients around the world while forging a sustainable, globally integrated value core.”

Jijun Yuan, CSO of Henlius, elaborated on the company’s differentiated innovation strategy: “Henlius’ R&D strength is reflected not only in our innovative pipeline but also in the continuous expansion of our platform capabilities. We focus on key therapeutic areas such as oncology and autoimmune diseases, extending our innovation reach to diverse modalities—including protein-based therapies, small molecules, and ADCs—to maximize synergistic potential across pipeline assets. Our three flagship technology platforms—the Hinova TCE (tri-specific T-cell engager) platform, the independently developed ADC platform Hanjugator™, and the AI-driven drug discovery platform HAI Club—have formed a collaborative R&D matrix. Leveraging these platforms and AI-driven approaches, we are accelerating the development of differentiated molecules, such as TCEs for solid tumors, to rapidly deliver more potential blockbuster therapies.”

In Henlius’ innovative pipeline, late-stage clinical assets such as HLX22 and HLX43 have emerged as breakthrough candidates, underscoring the company’s potential to drive future growth. Lixin Feng, Strategic Products Deputy GM of Henlius, shared that, “HLX43 is a precisely designed ADC targeting the pan-tumor antigen PD-L1. Its core framework incorporates the company’s proprietary novel anti-PD-L1 mAb, combined with MediLink Therapeutics’ innovative linker-toxin payload featuring a dual-release mechanism (intracellular and extracellular). As the world’s second and China’s first PD-L1 ADC to enter clinical development, HLX43 has demonstrated early potential as an innovative PIP (pipeline in a pill).Preclinical studies have shown favorable druggability and safety profiles with significant tumor-killing activity. Meanwhile, clinical studies of HLX43 as both monotherapy and in combination with HANSIZHUANG are accelerating across multiple solid tumors, with the potential to deliver superior treatment options for patients.” 

At the event, Professor Lin Shen, the leading principal investigator of the MRCT Phase 3 trial for HLX22, remarked: “Henlius’ HLX22 is a highly promising HER2-targeted therapy distinguished by both its mechanism of action and clinical performance. Its differentiated molecular design enables simultaneous binding to HER2 alongside trastuzumab, synergistically blocking all HER2 dimer formation and disrupting HER2-mediated signaling pathways. Moreover, HLX22’s clinical development strategy is both pioneering and ambitious—it targets gastrointestinal cancers, a field with urgent unmet needs and high heterogeneity, where the drug has demonstrated exceptional antitumor efficacy. This positions HLX22 to potentially redefine first-line treatment for HER2-positive gastric cancer. HLX22 has demonstrated clinical development potential as a pan-tumor therapeutic for all HER2-positive cancers. We look forward to HLX22 benefiting more patients worldwide.”

Henlius is strategically advancing key innovations in biopharma by harnessing AI to sharpen its cutting-edge capabilities. Simon Hsu, CTO and SVP of Henlius, highlighted breakthroughs in AI-driven drug development, with a focus on next-generation hyaluronidase Henozye™, “Utilizing AI modeling, Henozye™ achieved significantly faster development cycles versus conventional methods while demonstrating superior enzyme activity and stability. Its exceptional performance across buffer systems and co-formulations provides critical support for subcutaneous delivery—overcoming injection volume limits to enable high-dose drug development,” He emphasized that this hyaluronidase platform will transform the subcutaneous delivery market. “Through collaborative partnerships, we’re accelerating subcutaneous formulations for both novel drugs and biosimilars, extending product lifecycles sustainably.”

While deepening its presence in Europe and the U.S. and expanding into emerging markets in Southeast Asia, Henlius is advancing its Globalization 2.0 strategy with a focused breakthrough in the Japanese market. Leveraging the advantages of geographic proximity and ethnic similarity for clinical development, along with Japan’s status as the world’s third-largest pharmaceutical market—supported by an aging population and a robust universal healthcare system—Henlius positions Japan as a strategic stronghold for the global rollout of its innovative biologics.

Jin Li, Vice President of Henlius Regulatory Affairs, stated that “We are advancing our Internationalization 2.0 Strategy with Japan as a key market, leveraging the differentiated advantages of our core pipeline assets HLX22 (anti-HER2 mAb) and serplulimab (HLX10, anti-PD-1 mAb) in gastric cancer and lung cancer. We have initiated clinical trials in Japan to establish foundational support for indication development. Japan represents a strategic priority as a global pharmaceutical hub, offering unique opportunities through its aging population dynamics and innovative drug policy environment. We are systematically building local operational capabilities while strengthening our market position through innovative biologics. By integrating global clinical resources with localized strategies, we are creating an end-to-end value chain from clinical development to commercialization. As a Chinese biopharma innovator, we are reshaping the landscape in global markets through this approach.”

Henlius is committed to building a global innovation network and fostering an international collaborative ecosystem, setting a benchmark for partnerships spanning product development, market access, and localized operations. During the panel discussion moderated by Henlius SVP and Chief Business Development Officer, Ping Cao, 2022 Nobel Laureate and Palleon Co-founder Professor Carolyn Bertozzi, Palleon CEO James Broderick, MediLink CMO Steve Chin, KGbio CEO Sie Djohan and Sermonix Founder and CEO David Portman joined the discussion under the theme “Partnering for Success – Building a Global Biopharma Ecosystem.”

Professor Carolyn Bertozzi highlighted the critical role of sialoglycans in disease treatment, particularly their mechanism in tumor immune evasion and autoimmune diseases, as well as their vast potential as a cutting-edge global technology for novel drug development. Palleon is actively advancing its proprietary Enzyme-Antibody Glycan Ligand Editing (EAGLE) platform and has entered into collaborations with Henlius to develop bifunctional antibody-sialidase fusion proteins and human sialidase fusion protein HLX79 (E-602)—leveraging the EAGLE platform to target cancer and autoimmune diseases, respectively. 

During the follow-up discussion, panelists unanimously recognized Henlius’ comprehensive capabilities spanning cutting-edge innovation, clinical development, and manufacturing excellence, while particularly commending the team’s efficient collaboration and responsive partnership approach. Industry partners emphasized that their decision to collaborate with Henlius was rooted in strong confidence in the company’s fully integrated biopharmaceutical platform that covers the entire value chain from research to commercialization. With established expertise in antibody development and a demonstrated ability to execute rapid yet reliable clinical strategies, Henlius has built a world-class manufacturing quality system meeting international standards, creating a robust foundation for global commercialization. Ping articulated the company’s partnership philosophy: “We build on trust as our foundation, drive progress through efficiency, and connect through innovation.” This guiding principle continues to shape Henlius’ growing global collaborative ecosystem. Moving forward, the company remains committed to deepening complementary technology partnerships and accelerating exploration in frontier therapeutic areas. By leveraging its strong partner network, Henlius aims to enhance worldwide access to innovative therapies and deliver high-quality treatment solutions to patients across the globe.

In biopharmaceutical R&D, the translational gap from preclinical research to clinical application remains a persistent challenge across the industry. For Henlius, this very gap represents a critical breakthrough point to truly deliver clinical benefit by staying centered on the patient. At the close of the event, Jijun Yuan moderated a panel discussion on the theme “From Discovery to Delivery: Patient-Centric Innovation in Practice.” He was joined by Lei Tang, Head of Translational Medicine Unite China R&D at Sanofi; Li Peng, CSO of Palleon; Feng Ren, Co-CEO and CSO of Insilico; and Guoqiang Hua, Founder and Chairman of Dan1Med. Guests shared insights from the perspectives of multinational pharma, cutting-edge biotech, AI-driven biopharma company and technology platform company. Discussions spanned innovations in tools that enhance precision in clinical trial design, the acceleration of R&D through advanced AI-driven data strategies, and the current challenges faced. Ultimately, all perspectives converged on a shared vision: building a collaborative, barrier-free ecosystem is essential to truly achieving a seamless transition “from discovery to delivery.”

From biosimilars to first-in-class therapies, and from deepening presence in mainstream markets to expanding into multi-polar global markets, Henlius continues to push the boundaries of the industry with its multiple driving forces such as innovation and globalization. In 2025, Henlius will remain committed to its core theme of “Collaborate to Create”, further powering its innovation engine to accelerate the transformation from technological strength to clinical value. The company aims to drive explosive growth across its innovative pipeline while advancing both technological breakthroughs and international collaboration. Looking ahead, Henlius will continue to write a new chapter for China’s biopharmaceutical industry on the global stage—bringing Chinese innovation to contribute to the advancement of human health worldwide.

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 5 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company’s launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.

Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report

SHANGHAI, April 16, 2025 /PRNewswire/ — On April 15, 2025, Henlius (2696.HK) released the “2024 Environmental, Social, and Governance (ESG) Report” (hereinafter referred to as the “ESG Report” or “Report”). This marks the sixth consecutive year that the company has submitted an ESG-related report to global stakeholders, comprehensively showcasing Henlius’ remarkable achievements and steadfast commitment across 5 key ESG pillars: Product, Talent, Environment, Society, and Corporate Governance.

Together for Health

Guided by patient needs, Henlius has consistently strengthened its R&D innovation. In 2024, R&D investment reached RMB1.8405 billion. To date, the company has successfully launched 6 products across about 50 countries and regions, benefiting over 750,000 patients. Henlius continues to focus on therapeutic areas such as oncology and autoimmune diseases, rapidly advancing about 50 pipeline molecules. The company has achieved broad coverage in high-incidence cancers such as lung cancer, colorectal cancer, gastric cancer, and esophageal squamous cell carcinoma. Additionally, it is actively developing 5 orphan drugs and rare disease treatments across multiple therapeutic areas, including oncology, chronic inflammatory, and neurological diseases.

In terms of accessible healthcare, 5 of Henlius’ products have been included in China’s National Reimbursement Drug List (NRDL). Its trastuzumab biosimilar HANQUYOU has been covered by public health insurance in countries including China, the UK, France, and Germany. The PD-1 inhibitor HANSIZHUANG has been included in 118 provincial or municipal-level government-backed supplemental insurance programs (Huiminbao), making high-quality biologics more accessible. Furthermore, through collaborations with international partners such as Abbott and SVAX, Henlius is expanding into emerging markets like Latin America and the Middle East, bringing Chinese innovation to the world and improving global health.

Together for Talent Growth

Upholding a people-centric talent philosophy, Henlius is dedicated to building a diverse talent ecosystem. In 2024, women made up 53% of the workforce. The company released Diversity Policy and launched an internal platform called “H-Voice” to promote open, transparent communication and feedback channels. Henlius emphasized employee growth and development, supporting 144 employees in obtaining professional certifications. Through the online learning platform “Henlius Academy” and customized training programs, the company continues to build its talent pipeline and empower future development. In 2024, it reached an average training time of 70.37 hours per employee. In 2024, Henlius was recognized as one of HR Asia’s Best Companies to Work for in Asia for the third consecutive year and was also awarded one of Universum’s Most Attractive Employers for Chinese Students for the first time.

Together for a Green Future

Henlius understands the importance of green development and embeds environmental protection in its core values and practices. In 2024, the company invested RMB7.8445 million in environmental protection, up 26% year-over-year, underscoring its strong environmental commitment. Throughout the year, Henlius completed 230 lean improvement projects, achieving a 2.87% year-over-year reduction in comprehensive energy consumption, a 5.47% decrease in greenhouse gas emissions, and a 5.93% reduction in water consumption—contributing to cleaner air and water. The Songjiang Facility successfully passed ISO 14001:2015 environmental management system certification, a testament to its environmental standards in line with international best practices. Henlius also promoted green supply chain initiatives, with 80% of direct procurement suppliers signing on to green supply chain agreements, jointly advancing low-carbon transformation across the industry chain.

Together for a Thriving Community

Driven by its “patient-centric” public welfare philosophy, Henlius carried out numerous social care initiatives in 2024, with total charity donations reaching RMB134.84 million. The company continued its Breast Cancer Rural Healthcare Outreach Program, and hosted public awareness activities for breast cancer and International Lung Cancer Awareness Month, including a charity cycling event to promote healthy lifestyles and holistic patient care.

In supply chain management, Henlius adopted BI systems to enhance transparency. 80% of its local suppliers are now introduced into its GMP system, resulting in approximately RMB55.65 million in procurement savings. This continuous effort drives cost reduction, efficiency improvement, and enhances the stability of the supply chain.

Together for Stronger Governance

Henlius builds its ESG strategy on a foundation of compliance and governance, supported by a four-tier ESG governance structure. In 2024, the company held 2 dedicated ESG meetings and hosted its first company-wide ESG Culture Month, further embedding ESG practices into its operations. Henlius remains committed to responsible operations, conducting 99 compliance training sessions with a total of 4,569 attendants, with 100% of employees signing the Compliance Commitment Letter. The commercial team received targeted responsible marketing training through 39 sessions with a total of 4,867 attendants. In 2024, Henlius filed 22 patent applications and got 10 invention or utility model patents granted. The company also passed the ISO 27001:2022 information security management system recertification.

Driven by innovation, with accessibility as the goal, sustainability as the foundation, social responsibility as the driving force, and governance as the guarantee, Henlius continuously creates value for patients, employees, society, and the industry. Looking ahead, Henlius will stay true to its patient-centered mission, integrating ESG into its business development, and contributing more “Chinese strength” to global health to co-create a brighter future for human well-being.

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 5 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company’s launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.

Picarro Unveils PI5131-i for Precise Isotopic Analysis of Nitrous Oxide in the Field and Lab

New Mid-IR Analyzer Delivers the Precision and Long-term Stability Needed for Advancing Nitrogen Cycle Research

SANTA CLARA, Calif., April 16, 2025 /PRNewswire/ — Picarro Inc., a global leader in gas concentration and stable isotope analyzers, today introduced the PI5131-i Analyzer, a cutting-edge midinfrared (midIR) analyzer designed for fast, high-precision, simultaneous measurements of site-specific and bulk δ15N, δ15Nα,  δ15Nβ and δ18O in nitrous oxide (N₂O). These isotopomers of N2O can be used to probe sources and sinks in the global nitrogen cycle by identifying nitrification and denitrification processes in soils and water which are key in soil and agricultural science.

The Picarro PI5131-i is a cutting-edge mid-IR analyzer designed for fast, high-precision, simultaneous measurements of site-specific and bulk δ15N, δ15Nα, δ15Nβ and δ18O in N₂O
The Picarro PI5131-i is a cutting-edge mid-IR analyzer designed for fast, high-precision, simultaneous measurements of site-specific and bulk δ15N, δ15Nα, δ15Nβ and δ18O in N₂O

“With its industry-leading precision, simultaneous measurement capabilities, and reliable operation, the PI5131-i Analyzer is engineered for the most demanding field and laboratory applications,” said Milos Markovic, Ph.D., Senior Director of the Environmental Business at Picarro. “We’re excited to introduce this state-of-the-art analyzer, further strengthening our portfolio of real-time monitoring solutions that support crucial research.”

The PI5131-i: Advanced Capabilities for N₂O Analysis

The PI5131-i Analyzer integrates Picarro’s advanced mid-infrared Cavity Ring-Down Spectroscopy (CRDS) technology with significant software and hardware upgrades to earlier models. The PI5131-i is an ideal solution for discerning and measuring the source of N2O emissions through grab-sample measurements in the lab. The analyzer delivers the following precision for 10 min averages:

  • δ15N, δ15Nα, and δ15Nβ precision: 0.7 per mil
  • δ18O precision: 0.7 per mil
  • N₂O concentration precision: <0.05 ppb (within 10 minutes on average)

About Picarro

For more than 25 years, Picarro has been enabling scientists around the world to precisely measure greenhouse gas (GHG) concentrations, trace gases, and stable isotopes in the air we breathe, water we drink and land we harvest. Powered by our patented Cavity Ring-Down Spectroscopy (CRDS) technology, our industry-leading portfolio of solutions delivers ultra-sensitive detection of target molecules at parts-per-billion resolution or better. For more information about Picarro’s analyzers, visit www.picarro.com/environmental.

Media Contact:

Jake Thill
Director, Marketing Communications
Picarro, Inc.
jthill@picarro.com